PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer

Until recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limited improvement compared to best supportive care in second li...

Descripción completa

Detalles Bibliográficos
Autores principales: Resch, Irene, Shariat, Shahrokh F., Gust, Kilian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862914/
https://www.ncbi.nlm.nih.gov/pubmed/29606979
http://dx.doi.org/10.1007/s12254-018-0396-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862914/
https://www.ncbi.nlm.nih.gov/pubmed/29606979
http://dx.doi.org/10.1007/s12254-018-0396-y

Ejemplares similares